ThinkEquity, CL King Downgrade Natus Medical (BABY) Amid Outlook
Tweet
Share
E-mailGet Alerts BABY Hot Sheet
Price: $26.75 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Join SI Premium – FREE
Shares of Natus Medical (Nasdaq: BABY) are bouncing off session lows despite two intraday downgrades from ThinkEquity and CL King.
The stock is currently down 9.7 percent following preliminary Q3 results and updated Q4 and FY11 guidance this morning.
ThinkEquity reduced its investment rating on Natus from Buy to Hold and cut its price target on the stock from $16 to $7. CL King downgraded the stock from Buy to Neutral and suspended its $14 price target.
To track all the market-moving analyst action on shares of Natus Medical following its outlook, visit our Analyst Ratings page.
The stock is currently down 9.7 percent following preliminary Q3 results and updated Q4 and FY11 guidance this morning.
ThinkEquity reduced its investment rating on Natus from Buy to Hold and cut its price target on the stock from $16 to $7. CL King downgraded the stock from Buy to Neutral and suspended its $14 price target.
To track all the market-moving analyst action on shares of Natus Medical following its outlook, visit our Analyst Ratings page.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Core Natural Resources (CNR) to Neutral
- Morgan Stanley Downgrades Baidu (BIDU) to Underweight
- Jefferies Downgrades Pediatrix Medical Group (MD) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
ThinkEquity, CL KingSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
